{"id":800,"date":"2024-10-24T09:02:18","date_gmt":"2024-10-24T09:02:18","guid":{"rendered":"http:\/\/eurosoi.org\/?p=800"},"modified":"2024-10-24T09:02:18","modified_gmt":"2024-10-24T09:02:18","slug":"pmc-free-article-pubmed-google-scholar-48","status":"publish","type":"post","link":"https:\/\/eurosoi.org\/?p=800","title":{"rendered":"\ufeff[PMC free article] [PubMed] [Google Scholar] 48"},"content":{"rendered":"<p>\ufeff[PMC free article] [PubMed] [Google Scholar] 48. Brechbiel MW, et al..Lead(II) complexes of 1 1,4,7,10-tetraazacyclododecane-N,N,N,N?-tetraacetate: remedy chemistry and software to tumor localization with 203Pb labeled monoclonal antibodies. Inorg Chim Acta. 1995;239:43C51. [Google Scholar] 33. Yong K, Brechbiel MW. Towards translation of 212Pb like a medical therapeutic: getting the lead in! Dalton Trans. 2011;40:6068C6076. [PMC free article] [PubMed] [Google Scholar] 34. Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A. Pretargeted radioimmunotherapy in tumored mice using an in?vivo 212Pb\/212Bi generator. Nucl Med Biol. 2005;32:741C747. [PubMed] [Google Scholar] 35. Miao Y, Hylarides M, Fisher DR, et al..Melanoma therapy via peptide-targeted -radiation. Clin Malignancy Res. 2005;11:5616C5621. [PubMed] [Google Scholar] 36. Ruble G, Chuanchu W, Squire RA, Gansow OA, Strand M. The use of 212Pb-labeled AZD3839 free base monoclonal antibody in the treatment of murine erythroleukemia. Int J Radiat Oncol Biol Phys. 1996;34:609C616. [PubMed] [Google Scholar] 37. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, <a href=\"https:\/\/www.adooq.com\/azd3839-free-base.html\">AZD3839 free base<\/a> Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000;27:93C100. [PubMed] [Google Scholar] 38. Tan Z, Chen P, Schneider N, et al..Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human being prostate cancer in mice. Int J Oncol. 2012;40:1881C1888. <a href=\"http:\/\/www.e-prenoms.com\/\">Rabbit Polyclonal to CARD11<\/a> [PubMed] [Google Scholar] 39. Meredith RF, Torgue JJ, Rozgaja TA, et al..Security and end result actions of first-in-human intraperitoneal radioimmunotherapy with 212Pb-TCMC-trastuzumab. Am J Clin Oncol. 2018;41:716C721. [PMC free article] [PubMed] [Google Scholar] 40. Banerjee SR, Minn I, Kumar V, et al..Preclinical evaluation of 203\/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020;61:80C88. [PMC free article] [PubMed] [Google Scholar] 41. Stenberg VY, Larsen RH, Ma L-W, et al..Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate malignancy. Int J Mol Sci. 2021;22:4815. [PMC free article] [PubMed] [Google Scholar] 42. Kasten BB, Arend RC, Katre AA, et al..B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 2017;47:23C30. [PMC free article] [PubMed] [Google Scholar] 43. McNeil BL, Robertson AKH, Fu W, et al..Production, purification, and radiolabeling of the 203Pb\/212Pb theranostic pair. EJNMMI Radiopharm Chem. 2021;6:6. [PMC free article] [PubMed] [Google Scholar] 44. Bauer D, Blumberg M, K?ckerling M, Mamat C. A comparative evaluation of calix[4]arene-1,3-crown-6 as a ligand for selected divalent cations of radiopharmaceutical interest. RSC Improvements. 2019;9:32357C32366. [Google Scholar] 45. Abou DS, Thiele NA, Gutsche NT, et al..Towards stable chelation of radium for biomedical applications with AZD3839 free base an 18-membered macrocyclic ligand. Chem Sci. 2021;12:3733C3742. [PMC free article] [PubMed] [Google Scholar] 46. Henriksen G, Hoff P, Larsen RH. Evaluation of potential chelating brokers for radium. Appl Radiat Isot. 2002;56:667C671. [PubMed] [Google Scholar] 47. Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for a-particle radioimmunotherapy of malignancy. J Nucl Med. 2014;55:1492C1498. [PMC free article] [PubMed] [Google Scholar] 48. McDevitt MR, Ma D, Lai LT, et al..Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537C1540. [PubMed] [Google Scholar] 49. Miederer M, Henriksen G, Alke A, et al..Preclinical evaluation of the -particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Malignancy Res. 2008;14:3555C3561. [PubMed] [Google Scholar] 50. Graf F, Fahrer J, Maus S, et al..DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeff[PMC free article] [PubMed] [Google Scholar] 48. Brechbiel MW, et al..Lead(II) complexes of 1 1,4,7,10-tetraazacyclododecane-N,N,N,N?-tetraacetate: remedy chemistry and software to tumor localization with 203Pb labeled monoclonal antibodies. Inorg Chim Acta. 1995;239:43C51. [Google Scholar] 33. Yong K, Brechbiel MW. Towards translation of 212Pb like a medical therapeutic: getting the lead in! <a href=\"https:\/\/eurosoi.org\/?p=800\" class=\"btn btn-link continue-link\">Continue Reading<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-800","post","type-post","status-publish","format-standard","hentry","category-kiss1-receptor"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeff[PMC free article] [PubMed] [Google Scholar] 48 - JAK2 inhibitor against human prostate cancer cells<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurosoi.org\/?p=800\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeff[PMC free article] [PubMed] [Google Scholar] 48 - JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"og:description\" content=\"\ufeff[PMC free article] [PubMed] [Google Scholar] 48. Brechbiel MW, et al..Lead(II) complexes of 1 1,4,7,10-tetraazacyclododecane-N,N,N,N?-tetraacetate: remedy chemistry and software to tumor localization with 203Pb labeled monoclonal antibodies. Inorg Chim Acta. 1995;239:43C51. [Google Scholar] 33. Yong K, Brechbiel MW. Towards translation of 212Pb like a medical therapeutic: getting the lead in! Continue Reading\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurosoi.org\/?p=800\" \/>\n<meta property=\"og:site_name\" content=\"JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-24T09:02:18+00:00\" \/>\n<meta name=\"author\" content=\"info\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"info\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=800#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=800\"},\"author\":{\"name\":\"info\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"headline\":\"\ufeff[PMC free article] [PubMed] [Google Scholar] 48\",\"datePublished\":\"2024-10-24T09:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=800\"},\"wordCount\":579,\"articleSection\":[\"KISS1 Receptor\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=800\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/?p=800\",\"name\":\"\ufeff[PMC free article] [PubMed] [Google Scholar] 48 - JAK2 inhibitor against human prostate cancer cells\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\"},\"datePublished\":\"2024-10-24T09:02:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=800#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurosoi.org\\\/?p=800\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=800#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurosoi.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeff[PMC free article] [PubMed] [Google Scholar] 48\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/\",\"name\":\"JAK2 inhibitor against human prostate cancer cells\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurosoi.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\",\"name\":\"info\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"caption\":\"info\"},\"sameAs\":[\"http:\\\/\\\/eurosoi.org\"],\"url\":\"https:\\\/\\\/eurosoi.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeff[PMC free article] [PubMed] [Google Scholar] 48 - JAK2 inhibitor against human prostate cancer cells","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurosoi.org\/?p=800","og_locale":"en_US","og_type":"article","og_title":"\ufeff[PMC free article] [PubMed] [Google Scholar] 48 - JAK2 inhibitor against human prostate cancer cells","og_description":"\ufeff[PMC free article] [PubMed] [Google Scholar] 48. Brechbiel MW, et al..Lead(II) complexes of 1 1,4,7,10-tetraazacyclododecane-N,N,N,N?-tetraacetate: remedy chemistry and software to tumor localization with 203Pb labeled monoclonal antibodies. Inorg Chim Acta. 1995;239:43C51. [Google Scholar] 33. Yong K, Brechbiel MW. Towards translation of 212Pb like a medical therapeutic: getting the lead in! Continue Reading","og_url":"https:\/\/eurosoi.org\/?p=800","og_site_name":"JAK2 inhibitor against human prostate cancer cells","article_published_time":"2024-10-24T09:02:18+00:00","author":"info","twitter_card":"summary_large_image","twitter_misc":{"Written by":"info","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurosoi.org\/?p=800#article","isPartOf":{"@id":"https:\/\/eurosoi.org\/?p=800"},"author":{"name":"info","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"headline":"\ufeff[PMC free article] [PubMed] [Google Scholar] 48","datePublished":"2024-10-24T09:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/eurosoi.org\/?p=800"},"wordCount":579,"articleSection":["KISS1 Receptor"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurosoi.org\/?p=800","url":"https:\/\/eurosoi.org\/?p=800","name":"\ufeff[PMC free article] [PubMed] [Google Scholar] 48 - JAK2 inhibitor against human prostate cancer cells","isPartOf":{"@id":"https:\/\/eurosoi.org\/#website"},"datePublished":"2024-10-24T09:02:18+00:00","author":{"@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"breadcrumb":{"@id":"https:\/\/eurosoi.org\/?p=800#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurosoi.org\/?p=800"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eurosoi.org\/?p=800#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurosoi.org\/"},{"@type":"ListItem","position":2,"name":"\ufeff[PMC free article] [PubMed] [Google Scholar] 48"}]},{"@type":"WebSite","@id":"https:\/\/eurosoi.org\/#website","url":"https:\/\/eurosoi.org\/","name":"JAK2 inhibitor against human prostate cancer cells","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurosoi.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd","name":"info","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","caption":"info"},"sameAs":["http:\/\/eurosoi.org"],"url":"https:\/\/eurosoi.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=800"}],"version-history":[{"count":1,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/800\/revisions"}],"predecessor-version":[{"id":801,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/800\/revisions\/801"}],"wp:attachment":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}